M
Miso Kim
Researcher at Seoul National University
Publications - 9
Citations - 97
Miso Kim is an academic researcher from Seoul National University. The author has contributed to research in topics: Osimertinib & Brentuximab vedotin. The author has an hindex of 3, co-authored 9 publications receiving 45 citations. Previous affiliations of Miso Kim include New Generation University College & Seoul National University Hospital.
Papers
More filters
Journal ArticleDOI
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer
Sehui Kim,Ji Young Jang,Jaemoon Koh,Dohee Kwon,Young A Kim,Young A Kim,Jin Chul Paeng,Chan Young Ock,Bhumsuk Keam,Bhumsuk Keam,Miso Kim,Miso Kim,Tae Min Kim,Tae Min Kim,Dae Seog Heo,Dae Seog Heo,Doo Hyun Chung,Yoon Kyung Jeon,Yoon Kyung Jeon +18 more
TL;DR: PD-L1 enhances glycolysis in NSCLC by upregulating HK2, which might dampen anti-tumor immunity, and may contribute toNSCLC oncogenesis by inducing metabolic reprogramming and immune checkpoint.
Journal ArticleDOI
Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.
Yusoo Lee,Tae Min Kim,Tae Min Kim,Dong Wan Kim,Dong Wan Kim,So Yeon Kim,Miso Kim,Miso Kim,Bhumsuk Keam,Bhumsuk Keam,Ja-Lok Ku,Dae Seog Heo,Dae Seog Heo +12 more
TL;DR: Osimertinib is active against EGFR exon 20 insertion-mutant NSCLC and flexibly binds within drug-binding pockets in preclinical models and the IC50 ratios for mutant to wild-type cells were higher than those for third-generation EGFR TKIs.
Journal ArticleDOI
Clinical Application of Next-Generation Sequencing–Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies
Changhee Park,Miso Kim,Miso Kim,Min Jung Kim,Hyeongmin Kim,Chan Young Ock,Chan Young Ock,Bhumsuk Keam,Bhumsuk Keam,Tae Min Kim,Tae Min Kim,Dong Wan Kim,Dong Wan Kim,Jong Il Kim,Dae Seog Heo,Dae Seog Heo +15 more
TL;DR: Overall, the clinical use of a NGS panel in patients with advanced melanoma shows association with clinical outcomes and several therapeutic strategies.
Journal ArticleDOI
Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC.
Ha Ram Park,Tae Min Kim,Tae Min Kim,Yusoo Lee,So Yeon Kim,Seongyeol Park,Young Seok Ju,Miso Kim,Miso Kim,Bhumsuk Keam,Bhumsuk Keam,Yoon Kyung Jeon,Dong Wan Kim,Dong Wan Kim,Dae Seog Heo,Dae Seog Heo +15 more
TL;DR: In this article, acquired resistance mechanisms were analyzed using tumor and plasma samples before and after third-generation EGFR TKI treatment in four patients with de novo EGFRT790M-mutant NSCLC.
Journal ArticleDOI
A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
Miso Kim,Jeong Ok Lee,Jiwon Koh,Tae Min Kim,Ji Yun Lee,Yoon Kyung Jeon,Bhumsuk Keam,Dong Wan Kim,Jong Seok Lee,Dae Seog Heo +9 more
TL;DR: In this paper, the authors evaluated the efficacy and safety of brentuximab vedotin in patients with relapsed or refractory EBV-positive and CD30-positive lymphomas.